



WARNING LETTER

Customceutical Compounding

MARCS-CMS 610092 - AUGUST 25, 2020

1. The investigators observed poor practices during aseptic processing, including a technician failing to sanitize materials prior to placing them into the ISO 5 classified area. In addition, personnel engaged in aseptic processing exposed facial skin within the ISO 5 classified area.

4. Your firm used non-sterile cleaning wipes inside the ISO 5 aseptic processing area.

5. Personnel failed to adequately sanitize equipment held in your laminar flow hood. In addition, personnel did not allow adequate disinfectant contact time to achieve sporicidal effect.

t 國法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

3

Hawaii Health Systems Corporation dba Kona Community Hospital Pharmacy

WARNING LETTER

MARCS-CMS 611130 - FEBRUARY 01, 2021

4. Your firm used a non-sterile disinfectant within the ISO 5 aseptic processing area.

WARNING LETTER

Infuscience, Inc. dba Bioscrip Infusion Services

MARCS-CMS 609526 - DECEMBER 21, 2020

6. Materials or supplies were not disinfected prior to entering the ISO 5 classified aseptic processing areas from the ISO 7 classified areas.

7. Disinfectant contact time and coverage of the item intended to be disinfected were inconsistent with the manufacturer's and firm's instructions and there was no assurance that adequate levels of disinfection were achieved.

WARNING LETTER

Family Pharmacy of Statesville, Inc.

MARCS-CMS 611664 - NOVEMBER 06, 2020

1. Your firm did not use a sporicidal agent in the ISO 5 areas.

2. Your firm re-used bottles containing **(b)(4)**, for use in the ISO 5 area, without assurance that the bottles remained sterile after multiple uses In addition, commercially purchased sterile wipes, for use in the ISO 5 area, were stored in a manner which increases the potential for contamination to be introduced onto the wipes.

t 图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

5

Agenda

- Definition of decontamination
- The considerations prior to decontamination
- The methodology of decontamination
- Design & Development of Decontamination
 Process for Cleanroom (Grade B) Decontamination
- Design & Development of Decontamination Process for Clean Air Equipment (Isolator & RABS of Grade A)
- Validation of Decontamination Process.
- Conclusion

Definition of Decontamination

<u>Decontamination</u> – The overall process of removal or reduction of any contaminants (chemical, waste, residue or microorganisms) from an area, object, or person. The method of decontamination used (e.g. cleaning, disinfection, sterilization) should be chosen and validated to achieve a level of cleanliness appropriate to the intended use of the item decontaminated. ~ 2020 PIC/S 2nd draft annex I

Decontamination is a broadly defined term used to describe a variety of processes that reduce microbial populations without an expectation for total kill.¹ It is not a substitute for sterilization; a sterilization process should be used wherever possible. A variety of chemical agents and methods are used that vary depending upon the application. Decontamination is used for bioburden reduction of materials, equipment, and environments in support of sterile product manufacture:

- · For materials and surfaces that cannot be sterilized
- For materials and surfaces that do not require sterilization

¹ Sterilization is preferred over decontamination and should be utilized wherever possible, consistent with minimization of handling post-sterilization.

~ USP41 <1211>Sterility Assurance

Decontamination

A process that is designed to remove soil (includ ing microorganisms) and may consist of clean-

ing and/or disinfection.


~ PDA technical report 51

t 图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

7

Definition of Decontamination






Decontamination of controlled environments and non-product contact surfaces

- In conventional cleanrooms, including restricted access barrier systems (RABS), this is predominantly a manual process
 performed after cleaning of the room/production line
- Decontamination of items upon transition into an environment of higher classification
- Isolators commonly use an automated process
- Periodic decontamination of operator gloves during processing

Decontamination of product contact surfaces

- Large equipment (e.g., stopper bowls) can be manually sanitized on a frequent basis in addition to sterilization to avoid the extensive manipulation required for their installation post-sterilization²
- Re-decontamination of sterilized equipment after aseptic assembly or intervention
 Periodic decontamination of previously sterilized utensils prior to interventions

~ USP41 <1211>Sterility Assurance




The considerations prior to decontamination

t 團法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

9





The methodology of decontamination - Clean

- Disinfection

t團法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

Application Methods

Spraying:

- · Produce the best wetting of surfaces: Lager droplets
- · Lack mechanical actions: Not clean the surface


Mopping:

- · Mechanical action: remove residues, viable and non-viable contamination
- Not uniform wetting as spraying
- Not sufficient to provide the required amount of disinfectant agent contact time.

Wiping:

- As Mopping
- Smaller surfaces: door handle, return vents, equipment, carts and passthrough area.

PDA Technical Report no.70 /page.29



13

110TPDA04029

Application Methods

Fogging or Gassing:

- Excellent results but does require longer of time to ensure adequate distribution of the agent and sufficient surface contact time.
- · Fogging: Fine droplet; Gassing: gas form
- No mechanical force: Not clean the surface
- · Safety consideration
- Chemical agents commonly used gassing or fogging of clean rooms include the following:
 - Paraformaldehyde
 - Peracetic acid/ hydrogen peroxide
 - Phenols
 - Bleach (dilute solution of sodium hypochlorite, also called "liquid bleach".)
 - Quaternary ammonia
 - Vapor phase hydrogen peroxide (VHPH)
 - Gaseous chlorine dioxide
 - Ozone

PDA Technical Report no.70 /page.29 PDA Technical Report no. Appendix VIII page 62


t图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

15

Gassing - Paraformaldehyde

- · Large-scale clean room decontamination methodology for many years
- Heating of paraformaldehyde to release formaldehyde gas
- Portable fans are set up prior to the creation of the gas
- The utmost safety concern-a potential carcinogen



Ozone Gas

- Gassing small or large scale operations
- · Ozone is made by adding high voltage to oxygen
- High concentration of ozone gas (200 ppm or more, relative humidity of 80% or more)
- Safety concerns
- Residues that are left behind on product-contact surfaces are also a significant concern and must be evaluated.

Ozone is very reactive and because most pharmaceutical products are susceptible to ozone attack, product quality may be affected.

Gaseous Chlorine Dioxide

- Similar to paraformaldehyde or VPHP rather than wet droplet fogging, as it is a gas product
- Corrosion, residual and safety

PDA Technical Report no. Appendix VIII page 63

t 團法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

17

Wet Droplet Fogging


- Generation or vaporization of small liquid droplets from a chemical agent that is placed into an air steam by a generator that is linked to a fogging device.
- Droplets usually range in size from 10.0 to 25 .0 microns.
 - Dry Fog is a very fine fog with an average mean droplet diameter of 10 μ m or less.
- Portable fans are used to circulate the droplets throughout the room
- Efficacy is based on the fogging time and the chemical agent used.
 - Peracetic acid and hydrogen peroxide, sodium hypochlorides, phenols, and quaternary ammoniums are normally used
- Lightly coat all surfaces with a thin but constant layer of chemical agent for an extended period.
- Once inhalation concerns are acceptable, end users could enter areas and dry any surfaces that are not completely dried.
- Depending on the chemical agent used, corrosion and residual can be controlled. However, with overuse and without manual cleaning procedures, residues can build up over time and corrosion can occur.



PDA Technical Report no. Appendix VIII page 62

Vaporized Phased Hydrogen Peroxide (VPHP)

- Noncarcinogenic
- $H_2O_2 \rightarrow H_2O + O_2$
- Vaporized 35% hydrogen peroxide (250-1200 ppm) in to manufacturing areas through portable or fixed distribution systems but not a cleaning step
- Considered a disinfection step rather than a sterilization process
- Leaks to the external environment and clearance time should be tested and assessed properly to assure safety
- Conclusive studies proving validation of the system are specific to the operation and the setup where it will be used. Each area should be assessed for effectiveness in its own validation study



110TPDA04029

Types of Disinfecting Agents

Agents	Vegetative Micro- organisms	Bacterial, fungal spores	Ingredients	Example	
Sanitizer	\checkmark	×	Alcohols	70%EtOH 70%IPA (better than EtOH)	
	(+)		H ₂ O ₂	<3%	
		×	phenols	LpH	
Disinfectant			Quaternary ammonium	ABQ -50 Tego 2000	
	(++)		H ₂ O ₂	3%-5%	
			Sodium hypochlorite	bleach	
Creaticide	(+++)	\checkmark	Peracetic acid	Minncare Cold Sterilant	
Sporicide			Ozone	8% by weight	
	()		H ₂ O ₂	≥6%	

PDA Technical Report no.70 page.05 & 18, USP<1072> page.03



"Resistance"


Resistance to Disinfecting Agents in Aseptic Manufacturing Facilities




USP<1072> page.06

110TPDA04029

microorganisms usually not growing actively, so the selective pressure for the development of resistance is less profound. However, the most frequently isolated



110TPDA04029



			Min	Minimum Reduction			
Agent	ts	Contact time	PDA TR70	USP<1072>			
Sanitiz	zer	Sufficient (Max 90 sec) but < 120 sec	>1 Log	Vegetative: ≥ 3 Log			
DisinfectantSufficient (1-5min)but < 10min			>1 Log	Vegetative: ≥ 3 Log			
Sporicide Sufficient (1-5min) but < 10min			>1 Log	Vegetative: ≥ 3 Log Spore: ≥ 2 Log			
			PDA	Technical Report no.70 /page.10,1			
		TPDA 計劃法人 Totac	n Parentinal Drug Association 荷南利二副 七方 命	USP<107			
		TPDA 社團法人 Taken 中華無	n Parentarial Drug Association 菌製劑協會	USP<107			
king condi		e of disinfected surface ue wipe down	●Perenteral Drug Association 菌製劑協會 ●Concentration ●pH ●Temperature	USP<107			
prrosion: l etal surface emical in ofter, lower- ying: nyl, Plexigla ipolam, epo scoloring	encompatibilit encompatibilit grade metal + I as, Kydex, or staining:	e of disinfected surface ue wipe down ums ng pontaining products / IPA對 y with the surface: Me Peracetic acid/ H ₂ O ₂ / Alc	•Concentration •pH •Temperature 壓克力板有輕微腐蝕性 elting, softening, in	USP<107			
prrosion: l etal surface nemical in ofter, lower- ying: nyl, Plexigla ipolam, epo scoloring	tion • <u>Resid</u> •Inocul Rust or pittir s + Chlorine-co compatibilit grade metal + I as, Kydex, xy + or staining: ne	e of disinfected surface ue wipe down ums ontaining products / IPA對/ y with the surface: Me Peracetic acid/ H ₂ O ₂ - Peracetic acid/ H ₂ O ₂ / Alc	•Concentration •pH •Temperature 壓克力板有輕微腐蝕性 elting, softening, in	USP<107 110TPetc. PDA Technical Report no.70			
prrosion: l etal surface nemical in ofter, lower- ying: nyl, Plexigla ipolam, epo scoloring	tion • <u>Resid</u> •Inocul Rust or pittir s + Chlorine-co compatibilit grade metal + I as, Kydex, xy + or staining: ne	e of disinfected surface ue wipe down lums ng pontaining products / IPA對 y with the surface: Me Peracetic acid/ H ₂ O ₂ / Alc Peracetic acid/ H ₂ O ₂ / Alc	 Concentration pH Temperature 壓克力板有輕微腐蝕性 elting, softening, in sohols 殘留特性, 使用後 	USP<107			
prrosion: l etal surface nemical in ofter, lower- ying: nyl, Plexigla ipolam, epo scoloring	tion • <u>Resid</u> •Inocul Rust or pittir es + Chlorine-co compatibilit grade metal + I as, Kydex, exy + or staining: ne Disir Sanitizer	e of disinfected surface ue wipe down ums ontaining products / IPA對/ y with the surface: Me Peracetic acid/ H ₂ O ₂ / Alc	 Concentration pH Temperature 壓克力板有輕微腐蝕性 elting, softening, in sohols 殘留特性, 使用領 不殘留, 	USP<107 110TP etc. mmediate discoloring PDA Technical Report no.70 後需以70% IPA 擦拭			
prrosion: l etal surface nemical in ofter, lower- ying: nyl, Plexigla ipolam, epo scoloring	tion • Resid • Inocul Rust or pittin es + Chlorine-co compatibilit grade metal + I as, Kydex, xy + or staining: ne Disir	e of disinfected surface ue wipe down ums ng ontaining products / IPA對/ y with the surface: Me Peracetic acid/ H ₂ O ₂ / Alc Peracetic acid/ H ₂ O ₂ / Alc	 Concentration pH Temperature 壓克力板有輕微腐蝕性 elting, softening, in cohols 殘留特性, 使用領 不殘留, 殘留, 	USP<107 110TP etc. mmediate discoloring PDA Technical Report no.70 後需以70% IPA 擦拭 不需後續擦拭			
etal surface nemical in ofter, lower- ying: nyl, Plexigla ipolam, epo	tion • <u>Resid</u> •Inocul Rust or pittir es + Chlorine-co compatibilit grade metal + I as, Kydex, exy + or staining: ne Disir Sanitizer	e of disinfected surface ue wipe down lums ng ontaining products / IPA對/ y with the surface: Me Peracetic acid/ H ₂ O ₂ / Alc Peracetic acid/ H ₂ O ₂ / Alc nfection Agent Alcohols (EtOH, IPA) phenols	 Concentration pH Temperature 壓克力板有輕微腐蝕性 elting, softening, in cohols 殘留特性, 使用後 不殘留, 殘留, 殘留, 殘留, 殘留, 殘留, 殘留, 殘留, 殘留, 	USP<107 110TP etc. mmediate discoloring PDA Technical Report no.70 後需以70% IPA 擦拭 承需後續擦拭 建議擦拭			

Expiration

1.Disinfecting agents


- A. Not Opened: Manufacturer's expiration date
- B. Opened, diluted: in-house study.

2.Container

A. Bioburden level


3.Open bucket

A. Discard the contents upon completion of the cleaning operation



110TPDA04029

Design & Development of Decontamination Process for Cleanroom (Grade B) Decontamination




Equipment


Ceilings(not HEPA filters) \rightarrow Walls \rightarrow **Equipments** \rightarrow Floors

(Agents may degrade filter matrix) (Top to Bottom)

(Further to closer to the exit)

⁽TPDA) 中華無菌製劑協會 本資料非經許可不得翻印 15





PDA Technical Report no.70 /page 27

Decontamination of Materials

Curtains

- Material substrates: most vinyl
- · Difficult but critical activity: soft surface, rougher
- Clean: high-surfactant-based cleaning product or 70% IPA + mechanical force(wiping or mopping).
- Disinfectant/Sporicide: H2O2 or peracetic acid (normally a minimum of five minutes)
- Greater frequency than wall surface since they may come in contact with personnel more frequently.



PDA Technical Report no.70 /page.30

33

t 图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

Decontamination of Equipment Surfaces

Non-product-contact Equipment Surfaces

- Critical location (close to product-contact surfaces): do not leave the residue that may be transferred inadvertently to a product-contact-surface.
 - ✓ Chemical agent, fibers from wipes...
 - ✓ Preclean for any product spills, broken glass, torn stoppers, damaged caps and other foreign matter before attempting disinfection.

Work Surface

- Work tables ,carts and setup areas: near product or components that come in contact with product.
- Frequency of cleaning is normally daily but should be based on usage.

PDA Technical Report no.70 /page.31



Decontamination of Equipment Surfaces

Nonstructural Clean Room and Hard-to-Clean Surfaces

- Routinely clean and disinfection and the frequency should be based on environmental monitoring results and/or a risk-based analysis.
- The surface is visibly free from particulate and residue.

Routine Nonstructural Surfaces	Hard-to-Clean Surfaces
Tanks	Tops of doors
Carts	Tracks
Countertops	Conveyers
Racks	Phones
Packaged supplies on racks	Equipment feet and legs
Storage bins	Underside of tanks, carts, and equipment
Stairs	Wheels
Exterior of tubing or pipes	Incubators, refrigerators, and cold rooms
Work surfaces	
Non-product-contact surfaces	
Non-product-equipment	
Monitors, samplers, gauges	
Tools (sterilization may be required)	

t 图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

35

Hold Times For Cleaned Areas, Non-Product-Contact Equipment, and Utensils

Cleaned Area or facility

Studies should be based on viable and nonviable sampling performed after cleaning and disinfection and at or beyond the maximum time allowed between cleaning and sanitization.

• Include the normal level of non-production activities.

Non-product-contact equipment and utensils


Those materials should be stored in a manner that ensures integrity is maintained for the established hold times.

Return From a Shutdown

A shutdown is a planned or required stoppage of operations that is likely to compromise the environmental conditions in the classified area.

- · Regularly scheduled activities: preventive maintenance...
- Unscheduled activities: unexpected power outages...

Bring the area or facility back to a state of control in accordance with the area's environmental classification.



Design & Development of Decontamination Process for Clean Air Equipment (Isolator & RABS of Grade A)

Points to Consider for the Aseptic Processing of Sterile Pharmaceutical Products in Isolators (PTC-isolator)

t 團法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

39

Q: What are the special considerations for cleaning and disinfecting isolator interiors (nonproduct contact surfaces) prior to decontamination?

Recommendation

The qualification or validation of the cleaning and disinfecting of nonproduct contact surfaces should be based on risk assessment. The cleanliness of nonproduct contact surfaces should be visually verified, at the least.

Cleaning process

- a. Location of surface within the isolator
- b. Activities performed at given location
- 1. Process and product requirement 2. The design of the isolator interior
- 3. The surfaces to be cleaned
- c. Material surface quality and cleanability
- d. Effect of product or foreign material residue (including cleaning material residue) on decontamination process

PDA PtC-isolator/page 40

Disinfection process

• A disinfection process may establish a baseline prior to the decontamination of the isolator interior.

<text><text><text><text><text><text><text>

The decontamination process may depend on the level of bioburden

- Normal bioburden, common practice to apply at least the ISO 8 limit "in operation" for open and closed isolators with gloves.

Note: Current FDA guidance recommends a background environment of no less than ISO 8 in operation; current EU GMP Annex 1 recommends ISO 8 at rest (Grade D).

- Hold time prior disinfection (under the protection of the HEPA- different consideration from the normal operation in the isolator)
- Hold time after disinfection
- The bioburden is higher than the disinfection effectiveness →additional disinfection steps are required.

						Table 7: Maximum action limits for viable particle contamination					_	fection		
	Table E: Comparison of regulat		ulatory	Grade	Air sample	Air sample Settle plates (diam. 90 mm) cfu/4 hours ^(a) Contact plates (diam. 55mm), cfu/ plate ^(c) No growth ^(b)			-		effect	tiveness		
	FDA (particles per air		Active		cfu/m ³			-	_					
			arraction	Α										
			cubic meter)	action	B	10	5		5	-				
	ISO	USP	0 E um	Limits	C D	100 200	50 100		25 50					
	150	USP	0.5 µm	Limits		200	μm		50	Act	on			
	ISO 5	100	3,520	1	А	3,520	20							
	ISO 6	1,000	35,200	7	N/A					Alert				
	ISO 7	10,000	352,000	10	В	352,000	2,900		Norma	il 📗				
	ISO 8	100,000	3,520,000	100	С	3,520,000	29,000							•
	N/A	N/A	N/A	N/A	D	N/A	N/A		Biobu	iraen	PDA	A PtC-isola	tor/page 40-	-41

The design of the isolator interior should be adequate for the cleaning and disinfection process.

- Materials of construction of the isolator interior should be cleanable and resistant to cleaning and disinfectant chemicals, treatment, and process
- Surfaces should be smooth and nonporous
- Surfaces should drain properly and not pool or accumulate liquids
- Critical spaces (areas, surfaces, or environments that, if microbiologically or chemically contaminated, pose a risk of contamination to product or product contact surfaces) should be accessible to the cleaning procedure
- Areas within the isolator that expose product or generate or harbor foreign material should be limited



PDA PtC-isolator/page 41

(TPDA) 杜圖法人 Takwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

43

Q: What are the current options for isolator interior decontamination?

 Hydrogen peroxide


 Peracetic acid
 Peroxygen compound (powerful oxidizing agent)

$O_2^- + H_2O_2 \rightarrow OH^- + OH^- + O_2$


The presence of free radicals results in the oxidation of proteins, DNA, and other components within the spore leading to its inactivation.

Decontamination agents are typically dispersed in two basic states: gaseous and vapor phase. VHP decontamination is an extremely potent, complex process due to its biphasic nature [both liquid and vapor (gas) phases are typically present in the chamber].

> PDA PtC-isolator/page 43 PDA TR.51/page 8



Two main approaches for VHP vapor generation used in the industry




fog is termed "dry" or "wet" by the industry

- Wet: droplet sizes larger than approximately 15-20 µm
- Dry: a droplet size below 15 µm

flash vaporization of injected VHP.

An operating temperature too low or liquid dosing too high may result in VHP boiling that will affect the efficacy and may even lead to explosion! Although pure hydrogen peroxide solutions are not usually explosive at atmospheric pressure, equilibrium vapor concentrations of hydrogen peroxide above 26 mol per cent (40 weight per cent) become explosive in a temperature range below the boiling point of the liquid.

PDA PtC-isolator/page 44



110TPDA04029

Should empty isolator mapping of temperature and humidity be 0: performed as part of decontamination qualification studies?

Temperature mapping of isolators or decontamination chambers should be consistent with the requirements for decontamination. → Influence the amount of localized condensation



Water condensation forming, timelapse - Stock Video Clip -K007/9302 - Science Photo Library

The hottest areas, typically closest to the vapor inlet and any operating equipment, are potentially "worst case" because of reduced condensation.

It is important to maintain nearconstant room conditions to minimize process variability during the individual VHP process and between multiple VHP cycles over time

PDA PtC-isolator/page 45 Pharmaceutical Technology JANUARY 2020

Q: What conditions and configurations should be considered during decontamination cycle development and validation?

Decontamination Process

- Environmental conditions (temperature, humidity range, and variation)
- Fan or blower speed (fixed or variable) or isolators without a fan
- Decontamination agent concentration, dose levels, and rates of application

Load Configuration

- Minimum and maximum loads
- Load placement and orientation
- Characteristics of load materials

Material Properties

- Compatibility of materials with the decontamination agent or process
- Substances or materials on a surface that could adversely affect the decontamination process or outcome

- Exposure of material and load surfaces
- Extension of gloves
- Position of doors and openings
- Porosity of materials
- Stacking or placement of materials
- Wrapping or folding of wrapping materials that occlude surfaces from decontamination


PDA PtC-isolator/page 46

```
t Big 法人 Taiwan Parenteral Drug Association
中華無菌製劑協會
```

110TPDA04029

49

D-value on different materials





Q: What are the key differences between cycle development and cycle qualification?

Cycle development

- Involve the adjustments of conditions, parameters and setting.

Cycle qualification

- Documented evidence of the reliability and effectiveness
- Testing and monitoring is designed to confirm that the cycle is performing to specifications.
- For a production cycle, an **overage** of decontaminating agent and/or exposure time is typically included
- Decontamination cycles for critical areas used in aseptic processing are commonly validated to a 6 log reduction of the biological indicator.

PDA PtC-isolator/page 47

51

tml>LL图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

The potential impact and the likelihood of impact of cycle variables and conditions that may affect the performance of the cycle, including:

- Isolator loading configurations, placement, orientation, and loading of materials and equipment within the isolator (e.g., orientation, packaging, number of items)
- Biological indicator selection and placement
- Chemical indication selection and placement (Mapping for worst case location)
- Process parameters for qualification cycle and for production cycle
- Decontamination agent concentration, dose, and application rate
- Effect of decontamination agent and cycle on isolator interior, material, and equipment surfaces
- Process parameters for aeration and decontamination agent removal
- Effectiveness of decontamination agent
- Interference of the decontamination cycle effectiveness as a result of contact with the isolator interior, equipment, or material surfaces
- Systems and instrumentation in place to control the decontamination cycle
- Automation programs
- Air circulation fan and blower placement, configuration, and speeds
- Distribution of the decontamination agent throughout the isolator
- Temperature and humidity distribution throughout the isolator
- Bioburden within the isolator or on the surfaces within the isolator that require decontamination

PDA PtC-isolator/page 48

Q: Which BI should be used for cycle development and cycle qualification? What are the requirements for such a BI (e.g., spore count, D-value)?

	Selected Organism	ATCC Derivation
Peracetic acid Iydrogen peroxide	Geobacillus stearothermophilus	7953 or 12980 (Ph. Eur.)
not less than 10 Microbial count 50% and 300%. Bls should be h by the vendor p Carrier should b typically stainles Bl should consis the spores on th The consistency determining the Bl should be pa D-value of the E next in order to	andled and stored at temperatures rior to use. be made of a material that is also co ss steel. st of a monolayer of spores to guara ne carrier. y of BIs within one BI batch should b survival-kill window). cked in a material permeable for H ₂	cator control should be between and humidity conditions as specified ommonly used in the isolator, antee direct contact of the VHP to be checked prior to use (e.g., by ${}_{2}O_{2}$ and easy to handle in the lab. comparable from one validation to the
	t 團法人 Taiwan Parenteral Drug Associatio 中華無菌製劑協會	53

Two sources of variability in validation of decontamination cycle:

- A. The inherent variability of the BI
- B. Variability that may arise from the decontamination cycle setup and procedure.



Enumeration

The determination is the efficient removal of the spores from the carrier

USP <55> Biological indicators-Resistance performance test

<u>Mechanically disrupt</u> to achieve a homogeneous suspension of the spores

The number and output power of the transducers fitted in the ultrasonic Ultrasonic energy bath Ultrasonic frequency and the use of single or swept frequency Damping effects of equipment placed in the bath (e.g., plastic-coated racks should not be used as they absorb ultrasonic energy). Use of glass containers to maximize transmission of ultrasonic energy to the contents of the bottle or tubes Spacing of bottles containing the BIs in the bath. Bottles should be placed • in standardized positions and should not touch each other. Specification for the container. Height of the base of the bottle in the bath • will determine the position of the BI with respect to nodes and internodes of the ultrasonic waves and determine the intensity of the exposure of the BI to ultrasonic energy. This effect may be reduced in baths that employ a "frequency sweep" mode of operation. The addition of a surfactant to water in the bath The independent spore count should be between 50% and 300% of the manufacturer's stated value. PDA TR.51/page 29

> t图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

55

110TPDA04029


System D-Value Determination

The system D-value is an essential part of the quality control program aimed at determining batch-to-batch variation in BIs' resistance.

· Usually determined in a routine place in the isolator, not a hard-to-reach surface

The test method used to determine the system D-value should reflect as closely as possible actual sporicidal vapor phase process conditions present during routine production. The system D-value is unique to the specified generator/enclosure combination.

*vapor concentrations, temperature of air/surfaces, humidity, same chamber and gas generator positions



110TPDA04029

Worst case location determination studies should be conducted prior to BI lethality studies. The following are examples of lethality studies:

- Kill or no Kill of Bls
- simplest form of biological indicator challenge.

Timed Removal of BIs Throughout the Cycle

- Various types of death kinetics studies are based on BIs' timed removal.
- A fractional cycle approach involves the timed removal of BIs throughout the cycle, defining the BIs' lethality point. Once the lethality point has been established, a safety margin appropriate to the process may then be determined

Bls with Different Numbers of Spores

- Bls carrying different numbers of spores are available commercially (e.g., 3 log/4 log/6 log) to determine lethality.

Q: How should multiple BIs be used and evaluated during VHP decontamination cycle development and validation?

Recommendation

The exposure of multiple, usually three, BIs at given locations may be used to evaluate and qualify the effectiveness of the decontamination cycle.

BI location and placement

- Locations that will provide the best opportunity for identification of difficult to decontaminate surfaces.
 - Risk assessment of the isolator, including the configuration of the isolator, the composition and positioning of nonproduct contact surfaces that may impact the effectiveness of the cycle, and the condition and distribution of decontamination agent.
- Where difficult-to-decontaminate surfaces or locations are identified, placement of multiple (usually triplicate) BIs at individual locations during cycle development and qualification may provide information about the efficacy of the decontamination cycle.

 PDA PtC-isolator/page 5
社園法人 Takwan Parenteral Drug Association 59 中華無菌製剤協會

110TPDA04029

The failure to deactivate one or more of the BIs at a given location should be investigated. The outcome of the investigation should indicate whether the growth is due to the cycle failure or to a BI-related issue.

The investigation should consider conditions that may adversely affect the decontamination cycle, such as:

- Confirmation of indicator organism growth
- BI lot or batch variation
- BI D-value, population, and resistance
- BI preparation and handling
- BI spore clumping or occlusion (rogue spores)
- Review of handling, incubation, and recovery methods
- BI placement configuration and location
- Insufficient exposure to the decontamination agent

- Decontamination cycle parameters
- Decontamination agent concentration
- Decontamination agent application or injection
- Control and monitoring instrumentations and sensors
- Temperature or humidity changes
- Condition, bioburden, and cleanliness of the isolator interior
- Effect of decontamination agent retention

Q: What effect could oil-based HEPA-filter integrity agents have on the isolator decontamination cycle?

HEPA-filter testing is critical to ensure efficacy of the decontamination process, but it is also important to consider any potential contamination that could be introduced in the system by the procedures used to test the filters.

Any residue from HEPA-filter test- ing that might be trapped on filters or surfaces can be removed and that any remaining residue will not compromise subsequent decontamination cycles.

 oil-based material to test the filters, ensure that the filter does not retain any of the mate- rial, because it could interact with the VHP in the system and negatively impact the efficacy of the decontamination process

If the challenge aerosol is oil (DOP, PAO,) it will be captured and absorbed into the filter medium, and the filter needs to be permitted to "dry out" for some time after testing let the oil evaporate and pass through as a vapor. - ISPE HVAC

• HEPA-filter testing would, ideally, occur before requalification cycles.

PDA PtC-isolator/page 53

t 图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

110TPDA04029

61

Q: Should each load be qualified during the decontamination cycle qualification?

The variability of the load within the isolator should be minimized and controlled. \rightarrow a risk-based approach should be used to qualify the decontamination of these loads.


The requalification process should align with the original validation strategy. If the approach includes qualifying each presentation within the isolator, the requalification should mimic that approach.

- Rotating loads, where all loads are qualified over time. This approach is supported by data collection and risk-based principles. That is only possible with data and strong monitoring processes to ensure control of the process.
- Bracketing strategies (e.g., minimum and maximum loads) may also be employed with proper assessment.

PDA PtC-isolator/page 54

Validation of Decontamination Process.

t 图法人 Taiwan Parenteral Drug Association 中華無菌製劑協會



Documentation of final worst case of condition and configuration

63

Conclusion

t團法人 Taiwan Parenteral Drug Association 中華無菌製劑協會

Frequency For Cleaning And Disinfection

Several approaches

1. <u>Area classification</u> Most stringent cleaning and disinfection frequency for the most stringent area classification	Grade A: clean and disinfect daily Grade C: clean and disinfect weekly Grade D: clean and disinfect monthly
2. <u>Environmental Monitoring Data</u> Potential fluctuations in the levels and types of bioburden recovered as revealed by daily or periodic data trending and review.	Reduce established cleaning frequencies based on sustained satisfactory area performance.

65

110TPDA04029

Frequency For Cleaning And Disinfection

Several approaches

3. Risk-based Model


The risk of product exposure to the environment and personnel and the type of manufacturing conducted in the classified area.

- a. Within an aseptic manufacturing boundary (Grade $D \rightarrow$ grade C) : More frequently
- b. Manufacturing areas that are immediately adjacent and contiguous (via airlocks) with open aseptic processing areas (for example, Grade C and adjacent Grade A)
- c. Areas that support microbial growth include locations for charging of powdered media and/ or ingredients to vessels.
- d. The age of the building or a difficult-to-clean layout
- e. Microbial air or surface action level excursions, power and/ or HEPA filter failures, or periodic facility shutdowns.


	PDA Technical Report no.70 /page.35
tim法人 Taiwan Parenteral Drug Association 中華無菌製剤協會	67


110TPDA04029

Example risk-based approach for selection of routine cleaning and disinfection frequencies for classified manufacturing areas



PDA Technical Report no.70 /page.37





110TPDA04029

Reference

- Technical Report No. 70 Fundamentals of Cleaning and Disinfection Programs for Aseptic Manufacturing Facilities
- Technical Report No. 51 Biological Indicators for Gas and Vapor-Phase Decontamination Processes: Specification, Manufacture, Control and Use
- USP41 <1211>Sterility Assurance
- 2020 PIC/S 2nd draft annex I
- PDA Points to Consider for the Aseptic Processing of Sterile Pharmaceutical Products in Isolators
- PharmTech_NA_Jan2020_wm page 53-57

Thanks for Your Attention 謝謝聆聽



Q & A

t團法人 Taiwan Parenteral Drug Association 中華無菌製劑協會 73